2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR
  5. CCR6 Isoform
  6. CCR6 Antagonist

CCR6 Antagonist

CCR6 Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-151435
    CCR6 antagonist 1
    		Antagonist 99.30%
    CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
  • HY-162495
    IDOR-1117-2520
    		Antagonist 99.94%
    IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation.
  • HY-162495A
    (S)-IDOR-1117-2520
    		Antagonist 99.47%
    (S)-IDOR-1117-2520 is the S-isomer of IDOR-1117-2520 (HY-162495). IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation.
  • HY-176980
    CCR6 antagonist 4
    		Antagonist
    CCR6 antagonist 4 (compound OXM1) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 158 nM). CCR6 antagonist 4 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 4 can be used for chronic inflammatory diseases research.
  • HY-176979
    CCR6 antagonist 3
    		Antagonist
    CCR6 antagonist 3 (compound OXM2) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 166 nM). CCR6 antagonist 3 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 3 can be used for chronic inflammatory diseases research.